Buthionine sulfoximine enhancement of arsenic trioxide-induced apoptosis in leukemia and lymphoma cells is mediated via activation of c-Jun NH2-terminal kinase and up-regulation of death receptors

被引:61
作者
Chen, Duo [1 ]
Chan, Rosemarie [1 ]
Waxman, Samuel [1 ]
Jing, Yongkui [1 ]
机构
[1] CUNY Mt Sinai Sch Med, Dept Med, Div Hematol Oncol, New York, NY 10029 USA
关键词
D O I
10.1158/0008-5472.CAN-06-0409
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The mechanism of apoptosis induced by treatment with As2O3 alone or in combination with buthionine sulfoximine (BSO) was studied in NB4, U937, Namalwa, and Jurkat cells. As2O3 at concentrations < 2 mu mol/L induced apoptosis in NB4 cells and Namalwa cells but not in U937 and Jurkat cells. As2O3-induced apoptosis in NB4 cells and Namalwa cells correlated with increase of H2O2 and caspase activation without activation of c-Jun NH2-terminal kinase (JNK). BSO (10 mu mol/L) depleted the reduced form of intracellular glutathione without inducing apoptosis but synergized with 1 mu mol/L As2O3 to induce apoptosis in all four cell lines. This synergy correlated with JNK activation. Treatment with As2O3 plus BSO, but not with As2O3 alone, increased the levels of death receptor (DR) 5 protein and caspase-8 cleavage. The JNK inhibitor SP600125 inhibited the increase in DR5 protein and attenuated apoptosis induced by treatment with As2O3 plus BSO. These observations suggest that a DR-mediated pathway activated by JNK is involved in apoptosis induced by treatment with As2O3 plus BSO.
引用
收藏
页码:11416 / 11423
页数:8
相关论文
共 43 条
[21]   The PML-RARα fusion protein and targeted therapy for acute promyelocytic leukemia [J].
Jing, YK .
LEUKEMIA & LYMPHOMA, 2004, 45 (04) :639-648
[22]   Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo [J].
Jing, YK ;
Wang, L ;
Xia, LJ ;
Chen, GQ ;
Chen, Z ;
Miller, WH ;
Waxman, S .
BLOOD, 2001, 97 (01) :264-269
[23]   Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1 [J].
Kajiguchi, T ;
Yamamoto, K ;
Hossain, K ;
Akhand, AA ;
Nakashima, I ;
Naoe, T ;
Saito, H ;
Emi, N .
LEUKEMIA, 2003, 17 (11) :2189-2195
[24]   Arsenic trioxide-induced apoptosis is independent of stress-responsive signaling pathways but sensitive to inhibition of inducible nitric oxide synthase in HepG2 cells [J].
Kang, SH ;
Song, JH ;
Kang, HK ;
Kang, JH ;
Kim, SJ ;
Kang, HW ;
Lee, YK ;
Park, DB .
EXPERIMENTAL AND MOLECULAR MEDICINE, 2003, 35 (02) :83-90
[25]   Arsenic trioxide-induced apoptosis and its enhancement by buthionine sulfoximine in hepatocellular carcinoma cell lines [J].
Kito, M ;
Akao, Y ;
Ohishi, N ;
Yagi, K ;
Nozawa, Y .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 291 (04) :861-867
[26]   Comparative activity of melarsoprol and arsenic trioxide in chronic B-cell leukemia lines [J].
Konig, A ;
Wrazel, L ;
Warrell, RP ;
Rivi, R ;
Pandolfi, PP ;
Jakubowski, A ;
Gabrilove, JL .
BLOOD, 1997, 90 (02) :562-570
[27]   Clinical trials of arsenic trioxide in hematologic and slid tumors: Overview of the national cancer institute cooperative research and development studies [J].
Murgo, AJ .
ONCOLOGIST, 2001, 6 :22-28
[28]   Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species [J].
Nakazato, T ;
Ito, K ;
Ikeda, Y ;
Kizaki, M .
CLINICAL CANCER RESEARCH, 2005, 11 (16) :6040-6049
[29]   Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients [J].
Niu, C ;
Yan, H ;
Yu, T ;
Sun, HP ;
Liu, JX ;
Li, XS ;
Wu, W ;
Zhang, FQ ;
Chen, Y ;
Zhou, L ;
Li, JM ;
Zeng, XY ;
Yang, RRO ;
Yuan, MM ;
Ren, MY ;
Gu, FY ;
Cao, Q ;
Gu, BW ;
Su, XY ;
Chen, GQ ;
Xiong, SM ;
Zhang, TD ;
Waxman, S ;
Wang, ZY ;
Chen, Z ;
Hu, J ;
Shen, ZX ;
Chen, SJ .
BLOOD, 1999, 94 (10) :3315-3324
[30]   Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-xL [J].
Perkins, C ;
Kim, CN ;
Fang, GF ;
Bhalla, KN .
BLOOD, 2000, 95 (03) :1014-1022